2021•Journal of Experimental PharmacologyOpen access

Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration

Stephanie Kaiser, Sruthi Arepalli, Justis P. Ehlers

Abstract

Abstract: Age-related macular degeneration (AMD) is the most common cause of legal blindness in developed countries. Neovascular (ie, wet) AMD is currently managed with intravitreal therapy. Traditional treatments (ie, bevacizumab, ranibizumab, aflibercept) provide high-efficacy therapy but can also require frequent dosing. Newer and future anti-VEGF therapies aim to decrease injection frequency through eitherlonger half life or port-delivery systems (brolucizumab, conbercept, KSI-301, ranibizumab). This review outlines current anti-VEGF treatments and ways by which their duration might be extended. Keywords: anti-VEGF, wet age-related macular degeneration, brolucizumab, aflibercept, bevacizumab, ranibizumab, KSI-301

Open-access reader

About this research paper

What this paper is about

Why it matters

OpenAlex reports 86 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Ranibizumab, Macular degeneration, Aflibercept, Medicine, Bevacizumab, Blindness, Dosing, VEGF receptors